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Abstract 
Neoadjuvant chemotherapy (NAC) has become a standard therapy for patients with advanced breast cancer. Pathologi-
cal complete response (pCR) after NAC is an important prognostic indicator, but some patients with pCR continue to 
experience recurrence. So new predictive and prognostic markers in addition to pCR are needed following NAC for breast 
cancer. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can evaluate metas-
tases in the entire body simultaneously, and has several potential advantages over conventional imaging modalities. The 
purpose of this study was to evaluate whether FDG-PET/CT can determine NAC response and whether FDG-PET/CT can 
be a new prognostic marker. We imaged 83 breast cancer tumors with FDG-PET/CT, ultrasound (US), and magnetic reso-
nance imaging (MRI) to evaluate NAC efficacy. As we previously analyzed 110 breast cancers with FDG PET/CT, we defined 
a threshold of >1.7 maximum standardized uptake value (SUVmax) as abnormal fluorodeoxyglucose (FDG) uptake. After 
NAC, 16 (19.3 %) tumors had a complete response, 54 (65.1 %) had a partial response, 11 (13.3 %) showed stable disease, 
and 2 (2.4 %) showed progressive disease. One of the two patients with progressive disease had bone metastasis detected 
by FDG-PET/CT and was not operated on. Remote metastases were evident in 2.4 % of patients after NAC as determined 
by FDG-PET/CT. Overall, 17 patients had pathological complete response (pCR). The sensitivity of abnormal FDG uptake 
after NAC for non-pCR was 20.3 % and the specificity was 94.7 %. Patients with abnormal FDG uptake after NAC experi-
enced significantly more recurrences (P = 0.004) and more of them died (P = 0.010). Moreover, the difference in disease-
free survival was more significant in the estrogen receptor (ER)-negative group. FDG-PET after NAC may be more effective 
for predicting prognosis than for evaluating treatment response. This tendency was particularly remarkable in ER-negative 
breast cancer tumors. FDG-PET/CT is useful for reevaluating surgical applicability after NAC.
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Background
Neoadjuvant chemotherapy (NAC) has become a stand-
ard therapy for patients with locally advanced breast 
cancer or many lymph node metastases. NAC is use-
ful for increasing the rate of breast-conserving surgery, 
treating minimum metastases, which may cause patient 
death, predicting patient prognosis, and for evaluating 
tumor treatment response (Fisher et  al. 1998; Chollet 
et  al. 1997; Rastogi et  al. 2008; Vinnicombe et  al. 1996; 
Abraham et al. 1996). Recent studies that investigated the 
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prognostic effects of clinicopathologic factors in breast 
cancer patients with NAC have suggested that pathologi-
cal complete response (pCR) is an important prognos-
tic indicator (Chaturvedi et  al. 2005; Kuerer et  al. 1999; 
Buzdar et  al. 2005). However, some patients with pCR 
continue to experience recurrences (Gonzalez-Angulo 
et  al. 2005). Furthermore, many patients with non-pCR 
experience a good prognosis. Therefore, new predictive 
and prognostic markers in addition to pCR are sought 
following NAC for breast cancer.
Ultrasonography (US) and magnetic resonance imaging 
(MRI) have been widely used for measuring tumor size to 
determine NAC response. As breast cancers often metas-
tasize to the liver, lymph nodes, lung, and bone, this dis-
ease generally requires multiple imaging modalities, such 
as enhanced computed tomography (CT), abdominal 
US, and bone scintigraphy to detect metastases. Because 
fluorodeoxyglucose positron emission tomography/com-
puted tomography (FDG-PET/CT) can evaluate metas-
tases in the entire body at one time, we have previously 
performed FDG-PET/CT to evaluate NAC efficacy. We 
inject [18F] 2-fluoro-2-deoxy-d-glucose (FDG), which 
is similar to glucose, into the body. We photograph the 
entire body with CT. So we detect cancerous lesions 
using the intrinsic property of cancer cells in which they 
uptake 3–8 times more glucose than normal cells. FDG-
PET/CT has improved diagnostic strategies in cancer 
patients by identifying primary tumors and metastasis. 
A meta-analysis revealed that FDG-PET is a valuable 
tool for detecting breast cancer recurrence and metas-
tases (Isasi et al. 2005). Some studies have reported that 
FDG-PET may become the method of choice for assess-
ing asymptomatic patients with elevated tumor marker 
levels (Siggelkow et  al. 2004). Moreover, FDG-PET/CT 
was reported to be useful as a prognostic indicator for 
patients with primary breast carcinoma and high stand-
ardized uptake value (SUV), which represented a worse 
prognosis with respect to both overall and relapse-free 
survival (Oshida et al. 1998).
As FDG-PET/CT has potential advantages over con-
ventional imaging modalities, it may be useful for moni-
toring breast cancer treated with NAC. However, the 
effectiveness of FDG-PET/CT for evaluating NAC is 
controversial. For instance, Wahl et  al. reported that 
FDG-PET of primary breast cancers showed a signifi-
cant decrease in tumor glucose metabolism after effective 
treatment was initiated and tumor response was deter-
mined pathologically (Wahl et  al. 1993). Tateishi et  al. 
reported that the sensitivity of FDG-PET/CT for pCR 
was not acceptable, but the specificity was high (Tatei-
shi et al. 2012). Therefore, herein we analyzed 83 breast 
cancer tumors with NAC treated from 2006. The pur-
pose of this study was to evaluate whether FDG-PET/CT 
can determine NAC response and whether FDG-PET/
CT can be a new prognostic marker by comparing FDG 




The clinical characteristics of the 83 breast cancers are 
summarized in Table 1. As two patients had breast can-
cer in both breasts, we analyzed 83 total tumors. All 
patients were female and the median age was 54 (age 
range 30–75 years). The histologic subtype was invasive 
ductal carcinoma in 79 (95.2  %), invasive lobular carci-
noma in 1 (1.2 %), mucinous carcinoma in 1 (1.2 %), and 
apocrine carcinoma in 2 (2.4  %). Thirty-nine patients 
were treated with docetaxel followed by FEC (5-FU, epi-
rubicin, and cyclophosphamide), thirty-nine patients 
were treated with weekly paclitaxel docetaxel followed by 
FEC, and five patients were treated with other regimens. 
One patient was treated with trastuzumab.
All patients except one underwent surgery: 38 breast-
conserving surgeries with radiotherapy, 36 mastecto-
mies, or eight skin-sparing mastectomies with breast 
reconstruction.
After NAC, US, MRI, and FDG-PET/CT showed 16 
(19.3  %) complete responses (CR), 54 (65.1  %) partial 
responses (PR), 11 (13.3  %) stable disease (SD), and 2 
(2.4  %) progressive disease (PD). Two cases of PD were 
detected with bone metastases by FDG-PET/CT, even 
though the primary tumor shrunk after NAC (Fig.  1). 
One of the two patients did not undergo surgery and 
continued to be treated with chemotherapy. The other 
patient’s bone metastasis was doubted on FDG-PET 
after NAC.Though we suggested to her to continue 
chemotherapy, she strongly wanted to have a breast sur-
gery done, so we did the surgery. Her bone matastasis 
was definitively diagnosed 6  months later. We experi-
enced remote metastasis in 2.4 % of patients after NAC 
with FDG-PET/CT. The mean time interval from initial 
breast cancer diagnosis to first recurrence was 19 months 
(range 4–75 months). Overall, 23 patients (27.7 %) devel-
oped recurrence and 15 died from breast cancer during 
the follow-up period.
FDG‑PET/CT to predict pCR in breast cancer
In this study, we defined  >1.7 SUVmax as abnormal FDG 
uptake and ypT0/is ypN0 as pCR in accordance with the 
method section. pCR was observed in 14 patients (16.9 %; 
Table 2). Estrogen receptor (ER) status and human epider-
mal growth factor receptor 2 (HER2) status were signifi-
cantly associated with pCR. Abnormal FDG uptake after 
NAC might be associated with non-pCR, but this was not 
significant. Abnormal FDG uptake after NAC was analyzed 
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in the two groups according to pathologic results (pCR and 
non-pCR). We evaluated the proposition that the abnormal 
uptake after NAC can predict the non-pCR. The sensitivity 
Table 1 Clinical characteristics of the patient cohort










 T1 8 9.6
 T2 62 74.7
 T3 7 8.4
 T4 6 7.2
N status
 N0 40 48.2
 N1 32 38.6
 N2 7 8.4
 N3 4 4.8
Stage before NAC
 Stage II 68 81.9
 Stage III 15 18.1
Type of surgery
 Breast-conserving surgery 38 45.8
 Mastectomy 36 43.4
 Skin-sparing mastectomy 8 9.6
 No operation 1 1.2
Type of axial surgery
 Sentinel lymph node biopsy 15 18.1
 Axial dissection after sentinel lymph node biopsy 4 4.8
 Axial dissection 63 75.9
 No operation 1 1.2
Subtype
 Luminal A and luminal B 54 65.1
 Luminal HER2 6 7.2
 HER2 positive 10 12.0
 Triple negative 13 15.7
Nuclear grade
 I 37 44.6
 II 20 24.1
 III 20 24.1
 Unknown 6 7.2
FDG uptake
 Negative 0 0.0
 Positive 83 100.0
Regimens of NAC
 wPAC → FEC 39 47.0
 DOC → FEC 39 47.0
 FEC → DOC 2 2.4
 FEC → DOC + H 1 1.2
 FEC → PTX + Bev 1 1.2
 wPAC 1 1.2
Fig. 1 A 56-year-old woman with detected bone metastasis using 
FDG-PET/CT after NAC. a, b The abnormal FDG uptake of the primary 
lesion was 3.7 (a) before NAC and 1.4 (b) after NAC. c, d The abnormal 
FDG uptake of the axial lymph node was 6.1 (c) and disappeared after 
NAC. e, f Abnormal FDG uptake of the right ilium was not detected 
(e) before NAC and was 1.8 (f) after NAC. g Bone metastasis was 
varied in right ilium on MRI
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of that proposition was 20.3 % and the specificity was 94.7 % 
(Table 2). pCR with abnormal FDG uptake after NAC only 
occurred in one patient (Fig. 2). In this case, the reason for 
the abnormal FDG uptake was attributed to the fact that the 
primary tumor was too big and that macrophages and gran-
ulation tissue around the shrinking tumor were responsible 
for the FDG uptake. If the primary breast cancer doesn’t 
have abnormal FDG uptake accumulation after NAC, this 
does not indicate non-pCR due to low sensitivity; therefore, 
it is difficult to predict pCR with FDG-PET/CT. Thus, for 
predicting pCR, US and MRI may be more effective.
Correlation between abnormal FDG uptake after NAC 
and prognosis
Next, we compared disease-free survival (DFS) and over-
all survival (OS) (Table 3). Among the clinicopathologic 
variables investigated, N stage, clinical stage, and abnor-
mal FDG uptake after NAC were associated with DFS 
in the univariate analysis. Patients with the abnormal 
FDG uptake after NAC had significantly more recur-
rences (P  =  0.004, Fig.  3a). We hypothesized that pri-
mary pCR would be associated with DFS, but we could 
not prove a significant association because of the small 
number of primary pCR cases. When multivariate anal-
ysis was performed with prognostic variables, N stage 
and abnormal FDG uptake after NAC were identified as 
significant independent prognosticator in this small sub-
set of patients (N stage hazard ratio: 4.316, P  =  0.010; 
abnormal FDG uptake after NAC hazard ratio: 2.955, 
P = 0.014). As for OS, clinical N stage, clinical stage, and 
abnormal FDG uptake after NAC were associated with 
OS in the univariate analysis among the clinicopatho-
logic variables investigated. More patients with abnormal 
Table 2 A comparison of tumor responses
* Statistically significant values
PCR Non‑pCR P values
preT
 T1 3 5
 T2 10 52
 T3 0 7
 T4 1 5 0.2755
Stage
 II 13 55
 III 1 14 0.2438
Estrogen receptor
 + 6 56
 − 8 13 0.0026*
HER2
 0 7 52
 1 1 5
 2 0 5
 3 6 7 0.0184*
PET
 <1.7 13 51
 >1.7 1 18 0.1240
Fig. 2 A 55-year-old woman had pCR with abnormal FDG uptake. a 
The cancer was visualized by a big mass on MRI before NAC. b MRI 
after NAC; the breast cancer could not be detected, which we con-
sidered as a complete clinical response. c FDG-PET/CT before NAC; 
the SUVmax of the primary breast tumor was 14.3. d FDG-PET/CT after 
NAC; abnormal FDG uptake remained (1.7). e Pathological findings: 
the cancer cells were gone. Bar 100 μm
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FDG uptake after NAC died (P = 0.010, Fig. 3b). When 
multivariate analysis was performed with prognostic var-
iables, only abnormal FDG uptake after NAC was a sig-
nificant independent prognosticator (hazard ratio: 2.643, 
P = 0.029). As shown in Table 2, the tumor response was 
significantly different between ER-positive and ER-nega-
tive tumors. Comparing DFS of ER-positive and ER-neg-
ative patients, this significant difference disappeared in 
the ER-positive group and the significant difference was 
greater in the ER-negative group (Fig. 4). 
Discussion
In this study, we analyzed FDG-PET/CT after NAC in 
breast cancer tumors. The clinical benefit of FDG-PET/
CT includes the detection of the original lesion and 
metastasis to axillary lymph nodes, diagnosis of remote 
metastases, treatment effect measurement, and convales-
cence prediction (Minamimoto et  al. 2007). FDG-PET/
CT has also been applied to assess the stage of malignant 
viability as well as to monitor treatment response.
It is well known that breast cancer is a heterogene-
ous disease. Classification according to clinical subtype 
with ER and HER2 gained widespread acceptance and 
these tumors have been shown to differ in presenta-
tion, response, to treatment and prognosis (Straver et al. 
2010). Therefore, we must also accommodate for hetero-
geneity in treatment and assessment of breast cancer.
In this study, we set an SUVmax cutoff of 1.7. With 
respect to FDG-PET/CT, how to evaluate SUVmax is con-
troversial. Some researchers have assessed SUV as the 
SUV reduction rate, response rate, or delta SUV (Con-
nolly et al. 2015; Jung et al. 2010; Choi et al. 2010). Indeed, 
the reduction or difference in SUV before and after NAC 
may exactly correlate with tumor response. However, 
breast cancer has such heterogeneity that some tumors 
exhibit high SUV, while others show low initial SUV. 
Therefore, we examined the SUV minimum of the abnor-
mal FDG uptake in breast cancer and used a cut-off of 1.7.
We showed that FDG-PET/CT is useful for predict-
ing prognosis in our cohort; cases with abnormal FDG 
Table 3 The relationship between clinicopathologic factors and prognosis
* Statistically significant values
n DFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
P value Hazard ratio P value P value Hazard ratio P value
Age
 ≤45 15 0.858  0.219
 >45 67
T
 T1/2 69 0.078 0.112
 T3/4 13
N
 0 40 0.001* 4.316 0.010* 0.026* 2.927 0.113
 1/2/3 42
Stage
 II 67 0.037* 1.762 0.229 0.037 2.278 0.154
 III 15
ER
 + 63 0.858 0.524
 − 19
HER2
 0, 1 65 0.985 0.734
 2, 3 17
pCR
 + 17 0.388 0.996
 − 65
pSUV
 <1.7 63 0.004* 2.955 0.014* 0.010* 2.643 0.029*
 >1.7 19
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uptake had a significantly worse prognosis. A similar 
result was generated by the multivariate analysis. Some 
reported reduction of FDG uptake could be used as a 
predictive marker for DFS, and FDG uptake for 2 cycles 
of NAC was associated with shorter event-free sur-
vival with ER +/HER2- breast cancer (Jung et  al. 2010; 
Groheux et al. 2015).
Further in our study, as the significant difference disap-
peared in the ER-positive group on multivariate analysis, 
FDG uptake may represent poor-prognosis in the ER-
negative group. Even if the NAC effect is not evident in 
the ER-positive group, postoperative hormone therapy 
is often effective. This may be the reason why abnormal 
FDG uptake doesn’t necessarily indicate a poor progno-
sis. Some reported FDG-PET/CT findings may contrib-
ute to differentiation of luminal A and non-luminal A 
subtypes of invasive breast cancer (Miyake et  al. 2014). 
Moreover, FDG-PET/CT response may differ in ER-
positive and ER-negative tumors. In this study, we only 
evaluated the difference in ER-positive and ER-negative 
tumors. Some researchers have reported that FDG-PET/
CT during NAC may predict response in ER-positive/
HER2-negative and triple negative tumors, but not 
in HER2-positive breast cancer (Koolen et  al. 2013). 
Therefore, in the future, we want to evaluate differences 
according to subtype with more patients and a longer 
follow-up time.
Breast cancer bone metastases are harder to detect 
than liver or pulmonary metastasis with CT and US. 
Ohta compared 99Tcm-methylene diphosphonate bone 
scintigraphy with FDG-PET for diagnosing breast cancer 
bone metastasis, and determined a sensitivity of 77.7  % 
and specificity of 97.6 % for the latter, while the sensitiv-
ity of bone scintigraphy was 77.7  % and specificity was 
80.9 % (Ohta et  al. 2001). The sensitivity of osteoplastic 
and osteoclastic metastases are equal using both imaging 
modalities. However, the specificity of FDG-PET/CT was 
significantly better than bone scintigraphy (P = 0.0392); 
therefore, FDG-PET/CT can be considered a substitute 
for bone scintigraphy. Because FDG-PET/CT can evalu-
ate metastases in the whole body at one time, FDG-PET 
is useful for broad metastasis investigations in breast 
cancer patients. In the present study, we detected remote 
metastasis after NAC in 2.4 % of patients.
a
b
0 500 1000 1500 2000 2500 3000










































Fig. 3 Kaplan–Meier curves of disease-free survival (a) and overall 
survival (b) according to SUVmax
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Fig. 4 Kaplan–Meier curves of disease-free survival according to 
SUVmax in the ER-positive group (a) and the ER-negative group (b)
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Caudle et al. reported 59 cases with PD of 1928 (3 %) 
NAC-treated patients, but remote metastasis was evident 
in only three of 1928 patients (0.015  %) (Caudle et  al. 
2011). In our study, the remote metastasis frequency was 
2.4 %. Caudle et al. did not mention the modality used to 
generate the remote metastasis diagnosis, but our detec-
tion frequency was higher than they reported.
Conclusion
We examined the accuracy of FDG-PET after NAC for 
detecting metastases. FDG-PET after NAC was not suit-
able for treatment efficacy evaluation, but it was effective 
for predicting prognosis. Moreover, this tendency was 
particularly remarkable in ER-negative breast cancer. In 
addition, we determined a remote metastasis rate of 2.6 % 
after NAC, and in these cases we changed the treatment 
protocol to avoid surgery. As this study was retrospective 
and the number of the patients was small, the results of 
our study should be interpreted with causion. In conclu-
sion, FDG-PET/CT is useful for predicting the prognosis 
in NAC-received breast cancer patietnts and reevaluating 
operation applicability after NAC.
Methods
Ethics statement
This study was performed in accordance with the guide-
lines approved by the Ethics Committee of Tokyo Medi-
cal and Dental University (TMDU) and the Declaration 
of Helsinki for biomedical research involving human 
subjects, and was approved by The Institutional Review 
Board of TMDU. All patients had breast cancer and con-
sented to NAC and FDG-PET/CT. We contacted the 
patients and got the written informed consent of this 
study. But as we could not obtain some patients’ writ-
ten informed consent, the information of this study was 
posted in the hospital and on the website.
Patients
A retrospective analysis was performed on 81 consecu-
tive breast cancer patients who were treated with NAC at 
our institution from September 2006 to September 2013. 
As two patients had cancer in both breasts, we analyzed 
83 total breast cancer tumors. All patients were diag-
nosed with stage II or III breast cancer and underwent 
NAC, including a patient who was treated with NAC, 
but not surgery, because of progression during NAC. We 
observed these patients for a median of 50 months.
Clinicopathological evaluations
Baseline examinations were performed before the first 
cycle of chemotherapy and included a physical examina-
tion, mammography, US, enhanced MRI, and FDG-PET/
CT. Lymph node metastases were determined by US, 
MRI, PET, and fine-needle aspiration cytology. ER and 
progesterone receptor (PgR) status were evaluated by 
J-score. The J-score comprises proportional values irre-
spective of the intensity of stained nuclei, and the pro-
portion of cells stained in each specimen was recorded as 
0, none; 1, <1 %; 2, 1–10 %; 3, ≥10 %, as advocated and 
employed as cut-off points in previous reports (Umemura 
et al. 2006). HER-2 positivity was defined by immunohis-
tochemistry. After completion of NAC, clinical response 
was assessed using the Response Evaluation Criteria 
in Solid Tumors 1.1 by US and MRI. The exact defini-
tion of pCR in breast cancer is unclear (von Minckwitz 
et al. 2012). We adopted a pCR of ypT0/is ypN0, which 
means no invasive residual cancer in the breast and no 
infiltrated lymph node, but noninvasive breast residuals 
permitted.
NAC and surgery
NAC regimens consisted of both four cycles of an anthra-
cycline regimen and four cycles of a taxane regimen. 
Only one patient was treated with trastuzumab. After 
NAC completion, all patients except the patient with 
detected metastasis underwent either breast-conserving 
surgery with radiotherapy, mastectomy, or skin-sparing 
mastectomy with breast reconstruction. Breast recon-
struction was performed by a plastic surgeon. The deci-
sion to operate was made following discussion between 
the surgeon and patient.
Fdg‑PET/CT
PET/CT images were acquired using a PET/CT sys-
tem (Aquiduo; Toshiba Medical Systems, Tokyo, Japan) 
combining a full-ring PET scanner and a 16-row heli-
cal CT scanner. The maximal standardized uptake value 
(SUVmax) was used to evaluate FDG uptake in the pri-
mary breast cancer. SUVmax was calculated as follows: 
SUVmax  =  measured activity concentration [Bq/mL]/
(injected activity [Bq]/body weight [kg] ×  1000). Blood 
glucose levels were measured just before FDG injection 
to exclude hyperglycemic patients whose serum glucose 
concentrations exceeded 200 mg/dL. After fasting for at 
least 4  h, the patients received an intravenous injection 
of 18F-FDG (3.7 MBq/kg). Visual assessment of 18F-FDG 
uptake was determined by consensus by two radiologists 
(Machida et al. 2013).
Determination of the cutoff value for FDG‑PET/CT
As we previously analyzed 110 breast cancers with FDG 
PET/CT, breast cancer tumors that were smaller than 
2 cm and with an SUVmax <1.7, were all early stage breast 
cancers, such as either pN0, no lymph-vascular invasion, 
or low nuclear grade. Therefore, we defined >1.7 SUVmax 
as abnormal FDG uptake in this study.
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Statistical analysis
The Chi square test was used to evaluate clinicopatho-
logical characteristics. Kaplan–Meier test was used to 
evaluate DFS and OS in the univariate analysis. Cox 
proportional hazards regression analysis was used to 
evaluate the prognosis in the multivariate analysis. P val-
ues <0.05 were considered to indicate statistically signifi-
cant differences. All statistical analyses were performed 
using the SPSS software (IBM Corp, Armonk, NY, USA).
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